Boston Scientific (NYSE:BSX) Rating Lowered to "Hold" at Erste Group Bank

Key Points

• Boston Scientific's rating was downgraded from "buy" to "hold" by Erste Group Bank, indicating a cautionary stance on the stock.
• Despite the downgrade, Boston Scientific received positive assessments from other analysts, with Raymond James and Wells Fargo increasing their price targets and maintaining higher ratings.
• The company reported strong quarterly earnings, with $5.06 billion in revenue and $0.75 EPS, surpassing analysts' estimates.

Boston Scientific (NYSE:BSX - Get Free Report) was downgraded by investment analysts at Erste Group Bank from a "buy" rating to a "hold" rating in a report issued on Friday,Finviz reports.

BSX has been the subject of a number of other reports. Raymond James Financial lifted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Leerink Partners upped their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an "outperform" rating in a research report on Wednesday. Wells Fargo & Company raised their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Finally, Canaccord Genuity Group increased their price target on Boston Scientific from $131.00 to $132.00 and gave the company a "buy" rating in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and an average price target of $120.79.

Boston Scientific Price Performance

NYSE:BSX opened at $96.36 on Friday. The business's 50-day moving average is $103.10 and its 200 day moving average is $102.06. Boston Scientific has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a market capitalization of $142.78 billion, a P/E ratio of 57.36, a P/E/G ratio of 2.31 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the prior year, the firm earned $0.62 EPS. The company's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company's stock.

Institutional Trading of Boston Scientific

A number of hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its position in Boston Scientific by 12.0% during the 3rd quarter. GAMMA Investing LLC now owns 33,017 shares of the medical equipment provider's stock valued at $3,223,000 after purchasing an additional 3,531 shares during the period. Bank of New Hampshire increased its holdings in Boston Scientific by 9.7% during the third quarter. Bank of New Hampshire now owns 21,636 shares of the medical equipment provider's stock valued at $2,112,000 after buying an additional 1,912 shares during the period. Neville Rodie & Shaw Inc. lifted its holdings in Boston Scientific by 2.0% during the third quarter. Neville Rodie & Shaw Inc. now owns 46,385 shares of the medical equipment provider's stock worth $4,528,000 after buying an additional 925 shares during the period. Hobart Private Capital LLC boosted its position in Boston Scientific by 41.9% during the 3rd quarter. Hobart Private Capital LLC now owns 7,515 shares of the medical equipment provider's stock valued at $734,000 after acquiring an additional 2,220 shares in the last quarter. Finally, Caldwell Trust Co purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $528,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.